Published in Women's Health Weekly, January 25th, 2001
The study, the largest clinical trial to assess the cardiovascular risk of tamoxifen, is part of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial.
"We found that cardiovascular event rates were not statistically significantly different between women assigned to tamoxifen or placebo, independent of pre-existing coronary heart disease," stated Steven Reis, MD,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly